AG Fuchs Seating © TUD/Magdalena Gonciarz

Fuchs Group

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for life-threatening hematopoietic disorders such as leukemia and lymphoma. However, despite improved conditioning regimens, graft-versus-host disease (GvHD) – an attack of patient tissue by immune cells within the graft - remains a major complication affecting every second transplanted patient. Frequent resistance to current treatment options makes GvHD the leading cause of premature non-relapse mortality in HSC recipients followed by infection. Our group develops novel individualized cell-based therapeutics to combat the unmet clinical need for efficient treatment of GvHD and viral infection after HSCT. We work in close collaboration with the Good Manufacturing Practice (GMP) facility of the Center for Regenerative Therapies Dresden (CRTD).

learn more Fuchs Group

GMP Facility © GMP Facility CRTD

More about us

Get in touch!

If you have any questions regarding our research or if your are interested in a scientific collaboration please contact us.

Anke Fuchs © CRTD

Group Leader


Dr. Anke Fuchs

Advanced Cellular Therapeutics